PT-141 (Bremelanotide) 10mg Research Peptide
PT-141, also known by its INN name Bremelanotide, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. It is uniquely notable among research peptides for having received FDA approval in 2019 (Vyleesi) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — providing researchers with a thoroughly characterized clinical profile. Unlike PDE5 inhibitors, PT-141 acts centrally through the melanocortin system rather than through vascular mechanisms. This 10mg vial provides research-grade PT-141 at ≥99% purity, HPLC and MS/MS verified per batch.
Research Background
PT-141 was originally derived from Melanotan II and identified as an active metabolite with CNS-mediated sexual arousal effects in animal models. Phase 2 and Phase 3 trials leading to FDA approval studied its effects on sexual desire, arousal, and distress in women with HSDD, with statistically significant improvements versus placebo on the Female Sexual Function Index. Beyond its approved indication, research has explored PT-141’s MC4R-mediated effects on energy homeostasis, mood, and inflammation — areas relevant to the broader melanocortin receptor research literature.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 10mg per vial
- Storage: −20°C, protected from light
- CAS Number: 189691-06-3
- Molecular Weight: 1025.2 Da
Certificate of Analysis
All PT-141 vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
